SUBSCRIBE
SUBSCRIBE

Dana-Farber Cancer Institute

NEWS
Genetown
Molecular “Signature” for Rapidly Increasing Form of Esophageal Cancer Discovered, Dana-Farber Cancer Institute Study
March 25, 2013
 · 
1 min read
Genetown
Rheumatoid Arthritis Prevented in Mice: Infusions of Regulatory T Cells Turn Off Autoimmune Attack on Joints, Dana-Farber Cancer Institute Study
February 11, 2013
 · 
1 min read
Pharm Country
New Method Identifies Genes That Can Predict Prognoses of Cancer Patients, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and IRCM Study
January 28, 2013
 · 
1 min read
Genetown
Mutations Found in “Junk” DNA May be Driving Skin Cancers, Dana-Farber Cancer Institute Study
January 25, 2013
 · 
1 min read
Pharm Country
Some Men Complaint of Shortened Penis Following Prostate Cancer Treatment, Dana-Farber Cancer Institute and Brigham and Women’s Hospital Study
January 3, 2013
 · 
1 min read
Genetown
Blood Levels of Immune Protein Predict Risk in Hodgkin Disease, Dana-Farber Cancer Institute Study
December 11, 2012
 · 
1 min read
Genetown
High Carbohydrate Diet May Up Colon Cancer Risk, Dana-Farber Cancer Institute Study
November 8, 2012
 · 
1 min read
Genetown
Are Cancer Patients’ Hopes for Chemo Too High? Dana-Farber Cancer Institute Study
October 25, 2012
 · 
1 min read
Genetown
Cancer Study Points to Tighter Pairing of Drugs and Patients, Dana-Farber Cancer Institute Study
September 10, 2012
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
January 23, 2026
 · 
4 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
December 16, 2025
 · 
19 min read
Press Releases
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
December 16, 2025
 · 
19 min read
Press Releases
Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
December 8, 2025
 · 
7 min read
Press Releases
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
December 2, 2025
 · 
4 min read
Press Releases
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
November 20, 2025
 · 
4 min read
Press Releases
Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program
December 3, 2024
 · 
4 min read
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
October 15, 2024
 · 
4 min read
Pharm Country
Grant Awarded to Identify New Druggable Targets in Gastroesophageal Cancer
January 30, 2024
 · 
2 min read
Genetown
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
November 9, 2023
 · 
5 min read
Load More